Tuesday 19 July 2011

ICH Guidelines for Safety issues in Pharmaceutical Industry

S2(R1): Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
S3A: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies
S4: Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing).
S5(R2): Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility.
S6(R1): Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.
S8: Immunotoxicity Studies for Human Pharmaceuticals.
S9: Nonclinical Evaluation for Anticancer Pharmaceuticals.
S10: Photosafety Evaluation of Pharmaceuticals.

Thursday 16 June 2011

Regulatory Requirment for Medicinal Products


The regulatory requirment  is essantial for placing and maintaining a medicinal product on the market but it is becoming more and more complex. For a successful marketing and management of the life cycle of a medicinal product it is an essential to have a detailed knowledge of the regulatory framework and to be completely up-to-date with its constantly changing regulations. This guide for Knowledge of “ Requirment of  Drug Regulatory Affairs” was designed as a  Platform for everyday practice, which should make routine work easier, and also keeps the user well informed about changes in the legal andm regulatory environment.
The guide will help the regulatory affairs professionals to be aware of the “regulatory jungle”, make easy work in this area and make it more competent.
v  Different procedures for drug approval, and relevant legislation and requirements to be considered when submitting an application for Marketing Authorisation
v  Application for Marketing Authorisation and the accompanying documents which demonstrate quality, safety and efficacy.
v Marketing Authorisation for Special Drug Products

Wednesday 15 June 2011

Regulatory Authorities in Pharmaceuticals




USA : USFDA-United States Food And Drug Administration
United Kingdom : MHRA-Medicines and Healthcare Products Regulatory Agency
Australia: TGA-Therapeutic Goods Administration
South Africa: MCC-Medicines Control Council
Romania: NMA-National Medicines Agency
Nigeria: NAFDAC-National Agency for Food And Drug Administration and Control
Europe: EMEA-European Medicines Evaluation Agency
Uganda: NDA-National Drug Authority
Brazil: ANVISA-Agencia Nacional de Vigiloncia Sanitaria
Malaysia: DCA-Drug Control Authority
Philippines: BFDA-Bureau of Food and Drug Administration
Vietnam: MOH-Ministry of Health
Thailand: FDA-Food and Drug Authority
Sri Lanka: SPC-State Pharmaceutical Corporation
Zimbabwe: MCAZ-Medicines Control Authority of Zimbabwe
Singapore: HAS-Health Sciences Authority
Canada: TPP-Therapeutic Product Programme

Friday 10 June 2011

Role of Granulation Process in Pharmaceutical Industry


Granulation process  is a ‘‘ process whereby small particles are gathered into larger, permanent masses in which the original particles can still be identified.’’ Pharmaceutical granulation is the rapid breakdown of agglomerates is important to maximize the available surface area and aid in solution of the active drug. In ancient times the granulation process used within the pharmaceutical industry but in modern time, granulation technology has been widely used by a wide range of industries, such as Pharmaceutical. ‘‘granulated’’ material is derived from the Latin word ‘‘granulatum,’’ meaning grained. The fundamental research on mixing, segregation mechanisms of powder, surface chemistry, and material science are necessary to develop the theoretical framework of granulation technology. The granulated material can be obtained by direct size enlargement of primary particles, or size reduction from dry compacted material. These industries employ agglomeration techniques to reduce dust, provide ease of handling, and enhance the material’s ultimate utility. Granulation is process of particle designing.

Granulation methods:  Two types
1.  Wet methods which utilize some form of liquid to bind the primary particles.
2. Dry methods which do Granulation Minimizes the technical risks.

1. Wet granulation technology: It is employed low-shear mixers or the mixers/blenders normally used for dry blending such as ribbon mixers. There are a number of products currently manufactured using these low-shear granulators. The process control and efficiency has increased over the years; however, the industry has embraced high-shear granulators for wet granulation because of its efficient and reproducible process and modern process control capabilities.
2. Dry methods: Dry compaction technique like roller compaction is commonly used  in the Pharmaceutical  industry. There are a number of drug substances which are moisture sensitive and cannot be directly compressed.



Application of Granulation technology in Pharmaceutical Industry: Pharmaceutical granulation process is used for tablet and sometimes capsule dosage forms; however, in some applications the process is used to produce spherical granules for the modified release indications or to prepare granules as sprinkles to be used by pediatric patients.

Granulation of Pharmaceutical Compounds: Pharmaceutical compounds are granulated due to
1. To increase the uniformity of drug distribution in the product
2. To densify the material
3. To enhance the flow rates and rate uniformity
4. To facilitate metering or volumetric dispensing
5. To reduce dust
6. To improve the appearance of the product.
7.  Granulation encountered the incomplete description behavior of powders in general.

Various Drying Techniques for Granulation
Sr. No.
Granulation Techniques
Drying techniques
1
Wet granulation
Tray or fluid-bed dryer
Tray or fluid-bed dryer
Vacuum/gas stripping/microwave
Spray dryer
Extrusion/ Spheronization /Pelletization
2
Dry granulation Process
Direct compression
Slugging Mill
Roller compactor Compacts milled

.



Granulation Mechanisms:  These include wetting and nucleation, coalescence or growth, consolidation, and attrition or breakage. Initial wetting of the feed powder and existing granules by the binding fluid is strongly influenced by spray rate or fluid distribution as well as feed formulation properties, in comparison with mechanical mixing.

Role of Binders in wet-granulation process: Binders are adhesives that are added to solid dosage formulations. The primary role of binders is to provide the cohesiveness essential for the bonding of the solid particles under compaction to form a tablet. In a wet-granulation process, binders promote size enlargement to produce granules and thus improve flowability of the blend during the manufacturing process. Binders may also improve the hardness of the tablets by enhancing intragranular as well as intergranular forces. In a direct compression process, binders often act as fillers and impart compressibility to the powder blend. The cohesive properties of binders may reduce friability of the tablets and thus aid in their durability and elegance.

Examples:
 Natural Polymers:  Starch, Pregelatinized Starch
Synthetic polymers:  PVP, Methyl cellulose, HPMC
 New Natural and Synthetic binders:  Khaya gum, Leucaena leucocephala seed gum,   Anacardium occidentale gum, Gellan gum, Combination of detarium gum and veegum.
 New synthetic binders:  Maltrodextrins, Chitosan derivatives

Granulation techniques: The choice of granulation technique depends on various factors such as chemical and physical stability of the final dosage form, intended biopharmaceutical performance.
v  High- and low-shear granulation
v  Roller compaction
v  Spray drying
v  Fluid-bed granulation
v  Extrusion speronization
v  Melt granulation  and Pelletization
v  Effervescent Granulation

Granulation Characterization: Granulation is a process used to prevent segregation of formulation components in a powder blend, bulk volume of granulation, improve blend flow, content uniformity, compressibility, and other properties. Chemical properties are equally important due to their impact on specifications of a dosage form such as content uniformity, chemical purity, and in vitro performance. In vivo performance such as bioequivalence done because it determines whether a pivotal   bioequivalency batch passes or fails. Granule Size affect the dissolution performance which ultimately affect bioequivalence study. Physical characterization can be performed at molecular, particulate, or bulk (macroscopic) levels.  

Different Parameters and Methods for Characterization of Granules
Sr. No.
Parameters
Method
1
Particle Morphology
Optical microscopy
2
Particle Size Distribution
Sieve analysis, laser light scattering
3
Nature
Powder X-Ray Diffraction
4
Thermal Analysis
DSC, TGA, DTA
5
Identification
Near-infrared (NIR) spectroscopy
6
Surface Area
Gas adsorption
7
Granule Porosity
Mercury intrusion methods
8
Granule Strength
Development of a Formulation

9
Granule Flowability and Density

Mechanical Method, Hopper Method, Density Appratus

Thursday 9 June 2011

Formulation and Characterization of Chewable Tablet of Dicyclomine


Dicyclomine is a synthetic tertiary amine derivative that has been widely used in treatment of smooth muscle spasm of the Gastrointestinal tract.  As an antispasmodic and antimuscarinic agent, it probably works by specific anticholinergic effect (antimuscarinic) at the acetylcholine (ACh)-receptor sites. Now Dicyclomine tablets and syrups are available in Market. This work was carried out to formulate the chewable tablets (Non liquid dosage form) of dyclocmine. Chewable tablets are the non liquid oral dosage form which are to chewed not swallowed.  Geriatric and paediatric patients find it difficult to swallow conventional tablets. So in order to avoid this problem, chewable tablets are most pre-ferable to increase bioavailability and palatability. This is new formualation approch which may be used for further research. The chewable tablets of dicyclomine were prepared by using Mannitol along with cross povidone  in  different concentration ratios especially for paediatric use. Aspartame  and vanilla were used as sweeten-ing agent and flavouring agent respectively. The dissolution studies of dyclomine chewable tablet were performed on pH 1.2 and 6.8 . Chewable tablets that met the pharmacopoeial specifications for tablets, with 88% dissolved amount 

Sunday 15 May 2011

OcuPhor™ – The Future of Ocular Drug Delivery


OcuPhor™ – The Future of Ocular Drug Delivery
Satish Gupta, Rajendra Gurjar
Smriti College of Pharmaceutical Education, Indore

Abstract
Current methods for ocular delivery include topical administration (eye drops), subconjunctival injections, periocular injections, intravitreal injections, surgical implants, and systemic routes. However, all of these methods have limitations. Therapeutic levels of many drugs may be difficult to achieve in ocular tissues and systemic toxicities are of concern when the oral and intravenous routes of administration are used. Intravitreal injections, periocular injections, and sustained-release implants can be used to achieve therapeutic levels of drugs in ocular tissues, but invasive methods are inherently risky due to the potential for bleeding, infection, retinal detachment, and other local injuries. Eye drops are useful in treating conditions affecting either the exterior surface of the eye or tissues in the front of the eye, but cannot penetrate to the back of the eye for treatment of retinal diseases. To meet these needs a novel ocular iontophoresis system (OcuPhor TM) to deliver drugs safely and noninvasively to the back of the eye. OcuPhor TM Iontophoresis offers a non-invasive and reproducible means of delivering a model anionic drug to eye tissues, specifically to the retina/choroid

keyword:- OcuPhor, Iontophoresis , Ocular drug delivery








Introduction :
Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are the major causes of blindness in the United States and Europe. Posterior uveitis and retinitis secondary to glaucoma also contribute considerably to loss of vision. These conditions affect tissues at the back of the eye, where drug treatment is difficult to administer.
Current methods for ocular delivery include topical administration (eye drops), subconjunctival injections, periocular injections, intravitreal injections, surgical implants, and systemic routes. However, all of these methods have limitations. Therapeutic levels of many drugs may be difficult to achieve in ocular tissues and systemic toxicities are of concern when the oral and intravenous routes of administration are used. Intravitreal injections, periocular injections, and sustained-release implants can be used to achieve therapeutic levels of drugs in ocular tissues, but invasive methods are inherently risky due to the potential for bleeding, infection, retinal detachment, and other local injuries. Eye drops are useful in treating conditions affecting either the exterior surface of the eye or tissues in the front of the eye, but cannot penetrate to the back of the eye for treatment of retinal diseases. To meet these needs a novel ocular iontophoresis system (OcuPhor TM) to deliver drugs safely and noninvasively to the back of the eye. OcuPhor TM Iontophoresis offers a non-invasive and reproducible means of delivering a model anionic drug to eye tissues, specifically to the retina/choroid
OCUPHORTM OCULAR DRUG DELIVERY TECHNOLOGY
Iontophoresis is an active method of drug delivery which uses a small electrical current to transport ionized drugs into and through body tissues. Early ocular iontophoresis devices designed for animal studies were inconvenient and not standardized (making it difficult to achieve reproducible results) and were impractical for human use. These early devices produced very high current densities, which damaged eye tissues.  Iomed designed the OcuPhorTM ocular drug delivery system.
The OcuPhorTM system consists of
·         drug applicator,
·         dispersive electrode,
·         an electronic iontophoresis dose controller.
The drug applicator is a small silicone shell that contains a patented silver-silver chloride ink conductive element; a hydrogel pad to absorb the drug formulation; and a small, flexible wire to connect the conductive element to the dose controller. The drug pad is hydrated with drug solution immediately prior to use, and the applicator is placed on the sclera of the eye under the lower eyelid (Figure 1).












                                        Figure 1:- OcuPhorTM system
The eyelid holds the applicator in place during treatment, which usually takes less than 20 minutes.
Because iontophoretic drug delivery depends primarily on electrical current and dosing time, programming and setting the electronic controller can control drug dose and rate of administration.
Iomed's small, battery-powered controller delivers constant current and is designed to be placed conveniently away from the patient during a treatment session.
A dispersive pad is placed on the patient's skin and connected to the dose controller to provide a complete path for the electrical circuit.
An effective drug delivery system not only has to deliver therapeutic amounts of drug into target tissues, but also has to control the delivered dose and rate of dosing reproducibly.